Last updated: February 16, 2026
What is NDC 45802-0440?
NDC 45802-0440 corresponds to Apremilast (Otezla), an oral medication approved for the treatment of psoriatic arthritis, plaque psoriasis, and some forms of Behçet's disease. It is marketed by Amgen Inc. and was approved by the FDA in 2014.
Market Overview
Market Size and Demand
- In 2022, the global psoriasis market was valued at approximately USD 6 billion, with apremilast occupying a significant share.
- Estimated US sales for apremilast approached USD 2.3 billion in 2022, representing around 38% of the global psoriasis market (source: IQVIA).
- The drug's primary competitors include biologic therapies like adalimumab (Humira) and secukinumab (Cosentyx), which dominate the market but come with higher costs and administration burdens.
Geographic Breakdown
- US remains the largest market, accounting for over 50% of sales.
- Europe is the second-largest market with steady growth.
- Other regions (Japan, rest of Asia) are experiencing increasing adoption due to expanding access and increasing psoriasis prevalence.
Market Penetration Factors
- Oral administration favors patient adherence over injectable biologics.
- Efficacy and safety profile remain key to market retention.
- Patent life expiration varies across regions; US patent protections extend generally until 2028, with potential for extensions or legal challenges.
Current Pricing Landscape
List Price
- The average wholesale price (AWP) for a 30-tablet supply of apremilast 30 mg ranges from USD 1,200 to 1,400.
- The average monthly cost for patients is approximately USD 1,250, varying by pharmacy and payor contracts.
Reimbursement and Out-of-Pocket Costs
- Insurers negotiate discounts and rebates, reducing actual prices paid.
- Out-of-pocket costs for patients under commercial insurance typically range from USD 50 to 150 monthly.
- Medicare and Medicaid pricing involves statutory discounts, generally lowering net prices relative to AWP.
Market Trends and Drivers
- Increasing prevalence of psoriasis and psoriatic arthritis globally.
- Shift from biologics to oral therapies for less severe cases.
- Ongoing patent protections and no generic versions in major markets until 2028.
- Growing off-label uses and expansion in indications, such as Behçet's disease.
Price Projections (Next 5 Years)
| Year |
Estimated Average Wholesale Price (USD) |
Key Factors influencing price |
| 2023 |
1,250 |
Stable pricing; no generic competition; high demand |
| 2024 |
1,230 |
Slight discounts due to market competition; inflation adjustments |
| 2025 |
1,150 |
Potential pressure from biosimilars or generics in late-stage approval |
| 2026 |
1,100 |
Increased biosimilar development; patent protection likely until 2028 |
| 2027 |
1,050 |
Entry of biosimilars in select markets; negotiations drive discounts |
Note: Prices are nominal and subject to regional variations, insurer negotiations, and regional policy changes.
Competitive Positioning & Future Outlook
- The oral administration of apremilast grants it a competitive advantage over injectable biologics.
- The upcoming patent expiry in 2028 could open market opportunities for generics or biosimilars, potentially reducing prices by 50% or more.
- Innovation in molecular formulations or combination therapies could influence future pricing strategies.
Key Takeaways
- The current USD 1,250 wholesale price reflects a large market share with limited competition until 2028.
- Reimbursement discounts substantially lower net prices.
- The primary threat to sustained high prices is patent expiration and entry of biosimilars.
- Price declines could accelerate post-2028, influenced by market entry of generics.
- Market growth is supported by increasing disease prevalence and patient preference for oral therapies.
FAQs
1. When will generics or biosimilars for apremilast become available?
Biosimilar competition is unlikely due to the drug's molecular nature; however, generic versions are expected post-patent expiry in 2028.
2. How does insurance reimbursement affect the actual price paid?
Insurance negotiations, rebates, and discounts mean actual transaction prices are often 20-50% lower than AWP.
3. What factors could accelerate price declines before patent expiry?
Regulatory approvals for biosimilars, policy changes favoring biosimilar substitution, or new therapies with superior efficacy could reduce prices earlier.
4. How is market growth projected post-2023?
Market growth depends on psoriasis and psoriatic arthritis prevalence, drug adoption rates, and new indications, with projections suggesting steady growth due to increasing patient numbers.
5. Are there upcoming patent challenges that could affect pricing?
Patent challenges are common but depend on legal outcomes; extensions or litigation could influence the patent expiry timeline.
References
- IQVIA, "Global Psoriasis Market Report," 2022.
- FDA, "Apremilast (Otezla) Approval Details," 2014.
- Amgen, "Otezla Product Information," 2023.
- MedTrack, "Market Price Data," 2023.
- EvaluatePharma, "Biopharma Market Trends," 2022.
Note: All data are subject to change as market conditions evolve.
